An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels

被引：23
作者：
Roesner, Thies [1 ,2 ]
Derer, Stefanie [1 ,2 ]
Kellner, Christian [1 ,2 ]
Dechant, Michael [2 ,3 ]
Lohse, Stefan [1 ,2 ]
Vidarsson, Gestur [4 ,5 ]
Peipp, Matthias [1 ,2 ]
Valerius, Thomas [1 ,2 ]
机构：
[1] Univ Kiel, Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Univ Kiel, Dept Med Nephrol & Hypertens 4, Kiel, Germany
[4] Sanquin Res, Dept Expt Immunohaematol, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 161卷 / 02期
关键词：
rituximab; IgG3; complement-dependent cytotoxicity; chronic lymphocytic leukaemia; MONOCLONAL-ANTIBODIES; LYMPHOMA;
D O I：
10.1111/bjh.12209
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：282 / 286
页数：5
相关论文
共 7 条
  • [1] Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation
    Hayashi, Kazumi
    Nagasaki, Eijiro
    Kan, Shin
    Ito, Masaki
    Kamata, Yuko
    Homma, Sadamu
    Aiba, Keisuke
    CANCER SCIENCE, 2016, 107 (05): : 682 - 689
  • [2] Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9
    Taylor, Ronald P.
    Lindorfer, Margaret A.
    Cook, Erika M.
    Beurskens, Frank J.
    Schuurman, Janine
    Parren, Paul W. H. I.
    Zent, Clive S.
    VanDerMeid, Karl R.
    Burack, Richard
    Mizuno, Masashi
    Morgan, B. Paul
    CLINICAL IMMUNOLOGY, 2017, 181 : 24 - 28
  • [3] Low pH impairs complement-dependent cytotoxicity against IgG-coated target cells
    Dantas, Ezequiel
    Erra Diaz, Fernando
    Gerber, Pehuen Pereyra
    Merlotti, Antonela
    Varese, Augusto
    Ostrowski, Matias
    Sabatte, Juan
    Geffner, Jorge
    ONCOTARGET, 2016, 7 (45) : 74203 - 74216
  • [4] Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity
    Bil, Jacek
    Winiarska, Magdalena
    Nowis, Dominika
    Bojarczuk, Kamil
    Dabrowska-Iwanicka, Anna
    Basak, Grzegorz W.
    Sulek, Kazimierz
    Jakobisiak, Marek
    Golab, Jakub
    BLOOD, 2010, 115 (18) : 3745 - 3755
  • [5] Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression
    Shimada, Kazuyuki
    Tomita, Akihiro
    Saito, Shigeki
    Kiyoi, Hitoshi
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (03) : 455 - 457
  • [6] CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I
    Lindorfer, Margaret A.
    Beum, Paul V.
    Taylor, Ronald P.
    ANTIBODIES, 2013, 2 (04): : 598 - 616
  • [7] Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca2+mobilization and cytotoxicity in human NK cells
    Freitas Monteiro, Marta
    Papaserafeim, Maria
    Real, Aline
    Puga Yung, Gisella L.
    Seebach, Jorg D.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2020, 108 (04) : 1409 - 1423
1